KAM
DCPH

Kazazian Asset Management’s Deciphera Pharmaceuticals, Inc. Common Stock DCPH Stock Holding History

Kazazian Asset Management’s Portfolio DCPH Stock Details DCPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-7,000
Closed -$271K – 92
2018
Q3 		$271K Buy
+7,000
New +$259K 0.25% 72

Other funds holding DCPH

NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Kazazian Asset Management's DCPH Position: Q4 2018 in Review

Kazazian Asset Management sold out of Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) in Q4 2018, closing a stake of 7,000 shares — an estimated $271K sold.

Kazazian Asset Management first reported a position in DCPH in Q3 2018 and held it in 1 quarter. The position peaked at $271K in Q3 2018. 78 funds tracked by Wall St. Rank hold DCPH as of Q4 2018.

  • Kazazian Asset Management reported no remaining Deciphera Pharmaceuticals, Inc. Common Stock position as of Q4 2018 after selling out during the quarter.
  • Kazazian Asset Management sold 7,000 Deciphera Pharmaceuticals, Inc. Common Stock shares in Q4 2018, an estimated $271K.
  • Kazazian Asset Management first reported a position in Deciphera Pharmaceuticals, Inc. Common Stock in Q3 2018 and held it in 1 quarter.
  • Kazazian Asset Management's Deciphera Pharmaceuticals, Inc. Common Stock position peaked at $271K in Q3 2018.
  • 78 funds tracked by Wall St. Rank held Deciphera Pharmaceuticals, Inc. Common Stock as of Q4 2018.

Based on Kazazian Asset Management's 13F filing for Q4 2018, filed 14 Feb 2019.